Not Disclosed Neurodegeneration by Eli Lilly and Co for Neurodegenerative Diseases: Likelihood of Approval

Not Disclosed Neurodegeneration is under clinical development by Eli Lilly and Co and currently in Phase I for Neurodegenerative Diseases.

Biotech accelerator Blackbird Labs launches with $100m grant – Pharmaceutical Technology

The initial focus of the organisation is on inflammation and immunology, neurological diseases, genetic diseases, and cancer. Credit: PeopleImages via Getty Images. New life sciences

November 8, 2023

Solventum raises earnings forecast after first independent quarter

By the numbers Q2 sales: $2.08 billion 0.2% increase year over year Net income: $89 million 72% decrease year over year Solventum raised its sales

August 9, 2024

Elon Musk’s brain implant company raises $280M to fund clinical trials

Dive Brief: Elon Musk’s brain implant company has raised a $280 million series D funding round weeks after securing clearance to study its device in

August 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.